[Marrs JC, et al. Drugs Context. 2020;2a; Nexletol (package insert);8a,9a] Enlarge The mechanism of action of bempedoic acid (red rectangle) among other LDL-C-lowering agents (blue rectangles).

Discontinue bempedoic acid when pregnancy is recognized, unless the benefits of therapy outweigh the potential risks to the fetus. Based on the mechanism of action, bempedoic acid may cause fetal ...

Nexletol (bempedoic acid) is a prescription drug ... This is Nexletol’s mechanism of action (how the drug works in your body). When the liver makes less LDL cholesterol, the body produces ...

In March, this trial of 13,970 patients reported that bempedoic acid (Nexletol ... How sure is she about the mechanism? And will removing Lp(a) have unintended effects on LDL cholesterol?

Bempedoic acid has a novel mechanism of action that inhibits a cholesterol synthesis pathway by acting on ATP (adenosine triphosphate) citrate lyase, a citrate-degrading enzyme in the liver.

For those who can’t take them, the best effects will be seen when bempedoic acid is combined with other cholesterol-lowering action. Prof Ray calls it ‘frustrating’ when patients can’t ...

The US Food and Drug Administration (FDA) has approved an updated low-density lipoprotein (LDL)-cholesterol lowering indication for bempedoic acid (Nexletol ... target action date for the ...

Bempedoic acid may be an alternative for people who need to lower their cholesterol but can’t or won’t take statins, according to a large study published Saturday in the New England Journal of ...

The FDA approved label expansions for bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet) so they can be used more broadly as cardiovascular prevention drugs, Esperion announced Friday.

About The Study: The findings of this study suggest that treatment with bempedoic acid in high-risk primary prevention patients unable to tolerate recommended doses of statins has the potential to ...

Bempedoic acid lowers cholesterol, and a study found a modest effect on cardiac illness. But whether patients are any more willing to take it remains to be seen, experts said. By Gina Kolata ...